Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1. Almac Discovery focuses on protein homeostasis and next-generation antibody drug conjugates. Their ...

for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1. Almac Discovery focuses on protein homeostasis and next-generation antibody drug conjugates. Their portfolio of ...

Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts. Despite clinical and regulatory risks ...

and dropping development of its former chief asset—the ROR1-targeted CAR-T candidate LYL797—in favor of the next-gen ROR1 candidate LYL119. The company also scrapped work on its tumor ...

Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC ...

6. Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner Radiance Biopharma is paying $15 million upfront for rights to a ROR1-directed antibody-drug conjugate from a ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC ...

BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...